Skip to main content
. 2021 Nov 22;12(6):852–859. doi: 10.4103/idoj.IDOJ_49_21

Table 3.

Complications related to treatment****

IL SSG Systemic SSG
Occurrence of side effects 77.26% (n=265/343) 72.72% (n=24/33)
Pain +++ Pain++Raised liver enzymes +++
Hyperpigmentation+++ Headache & Giddiness+++
Hypertrophic & atrophic scars+++ Fainting+Myalgias +++
Milia++ Hyperpigmentation +++
Raised liver enzymes - Hypertrophic & atrophic scars +++
Postural hypotension+
Headache & Giddiness -
Myalgias -
Relapse of disease None at 6 months None at 6 months

****Many patients experienced more than one side effect of therapy. +++ Very common; ++ Common; + Less common; Nil. SSG: Sodium stibogluconate